A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Recruiting · Phase 1 · NCT05137054
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $4.1M
- U.S. investigators named
- 14
- Sites paid
- 13
- Planned or actual enrollment
- 317
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Linvoseltamab (drug), Daratumumab (drug), Carfilzomib (drug), Lenalidomide (drug), Bortezomib (drug), Pomalidomide (drug), Isatuximab (drug), Fianlimab (drug), Cemiplimab (drug), Nirogacestat (drug), Cevostamab (drug)
- Dates
- Started 2022-08-17; completion 2032-03-24
- Results posted
- Not yet
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with ot…
From ClinicalTrials.gov, last updated 2026-11-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $4.1M in research payments for this study in 2025 (1,408 payments).
Products named: Lynozyfic
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nisha S. Joseph, M.D. Medical Oncology · Atlanta, GA
- Attaya Suvannasankha, M.D. Hematology & Oncology · Indianapolis, IN
- Clifton C. Mo, M.D. Medical Oncology · Boston, MA
- Jeffrey A. Zonder, MD Hematology & Oncology · Detroit, MI
- Joselle Cook, M.B.B.S. Hematology · Rochester, MN
- Shaji K. Kumar, M.D. Hematology · Rochester, MN
- John T. Mckay, D.O. Hematology & Oncology · Winston Salem, NC
- Samuel M. Rubinstein, M.D. Internal Medicine · Chapel Hill, NC
- Rajshekhar Chakraborty, MD Medical Oncology · New York, NY
- Ruben Niesvizky, MD Hematology & Oncology · New York, NY
- Naresh Bumma, M.D. Hematology · Columbus, OH
- Aimaz Afrough, M.D. Hematology · Dallas, TX
- Nicholas R. Burwick, M.D. Hematology & Oncology · Seattle, WA
- Madhav V. Dhodapkar, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Weill Medical College of Cornell University $937,720
- Trustees of Columbia University $659,842
- Wake Forest University Health Sciences $554,280
- Dana Farber Mass General Brigham Cancer Care Inc $425,118
- Mayo Clinic $398,904
- Emory University Hospital, GA $365,516
- The Ohio State University Office of Sponsored Programs $320,395
- Karmanos Cancer Center, MI $163,937
- University of North Carolina at Chapel Hill $127,073
- The University of Texas Southwestern Medical Center at Dallas $99,890
- Trustees of Indiana University $54,500
- Seattle Institute for Biomedical and Clinical Research $26,551
- Scripps Mercy Hospital, CA $4,100
- $2,842
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.